# A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease

> **NCT03998514** · PHASE1 · COMPLETED · sponsor: **CohBar, Inc.** · enrollment: 88 (actual)

## Conditions studied

- Nonalcoholic Fatty Liver Disease

## Interventions

- **DRUG:** CB4211 Dose 1
- **DRUG:** CB4211 Dose 2
- **DRUG:** CB4211 Dose 3
- **DRUG:** CB4211 Dose 4
- **DRUG:** CB4211 Dose 5
- **DRUG:** CB4211 Dose 6
- **DRUG:** CB4211 Dose TBD
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03998514
- **Lead sponsor:** CohBar, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-09
- **Primary completion:** 2021-04-19
- **Final completion:** 2021-04-19
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2021-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03998514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03998514, "A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03998514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*